The global Chemotherapy Induced Peripheral Neuropathy Treatment market is projected to grow from US$ 1791.4 million in 2024 to US$ 2599.2 million by 2030, at a Compound Annual Growth Rate (CAGR) of 6.4% during the forecast period.

Chemotherapy Induced Peripheral Neuropathy Treatment Market

CIPN is a common adverse effect of several cancer therapies including taxanes and platinum drugs. Symptoms include decreased sensation and tingling of the hands and feet, severe pain, numbness and muscle weakness, all of which can occur during cancer treatment, and frequently persist after chemotherapy has ended.

There are no approved therapies to combat the debilitating symptoms of CIPN now. Current alternatives include Palliative care using antidepressants, antiepileptic drugs, or opioids, all of which have well known adverse side effects.

Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.

The key players are Aptinyx Inc, Asahi Kasei Pharma Corp, Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor etc.

Report Covers:

This report presents an overview of global market for Chemotherapy Induced Peripheral Neuropathy Treatment, sales, revenue and price. Analyses of the global market trends, with historic market revenue/sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Chemotherapy Induced Peripheral Neuropathy Treatment, also provides the sales of main regions and countries. Highlights of the upcoming market potential for Chemotherapy Induced Peripheral Neuropathy Treatment, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Chemotherapy Induced Peripheral Neuropathy Treatment sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Chemotherapy Induced Peripheral Neuropathy Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type, and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Chemotherapy Induced Peripheral Neuropathy Treatment sales, projected growth trends, production technology, application and end-user industry.

Market Segmentation

Scope of Chemotherapy Induced Peripheral Neuropathy Treatment Market Report

Report Metric	Details
Report Name	Chemotherapy Induced Peripheral Neuropathy Treatment Market
Accounted market size in 2024	US$ 1791.4 million
Forecasted market size in 2030	US$ 2599.2 million
CAGR	6.4
Base Year	2024
Forecasted years	2024 - 2030
Segment by Type	Calcium Channel α2-delta Ligands Antidepressants Opioids Others
Segment by Application	Platinum Agents Taxanes Vinca Alkaloids Others
Segment by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Rest of Europe Nordic Countries Asia-Pacific (China, Japan, South Korea) Southeast Asia (India, Australia) Rest of Asia Latin America (Mexico, Brazil) Rest of Latin America Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of MEA)
By Company	Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, and by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Sales (consumption), revenue of Chemotherapy Induced Peripheral Neuropathy Treatment in global, regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 3: Detailed analysis of Chemotherapy Induced Peripheral Neuropathy Treatment manufacturers competitive landscape, price, sales, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the sales, revenue, average price, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America (US & Canada) by Type, by Application and by country, sales, and revenue for each segment.
Chapter 7: Europe by Type, by Application and by country, sales, and revenue for each segment.
Chapter 8: China by Type, and by Application, sales, and revenue for each segment.
Chapter 9: Asia (excluding China) by Type, by Application and by region, sales, and revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by Type, by Application and by country, sales, and revenue for each segment.
Chapter 11: Provides profiles of key manufacturers, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Chemotherapy Induced Peripheral Neuropathy Treatment sales, revenue, price, gross margin, and recent development, etc.
Chapter 12: Analysis of industrial chain, sales channel, key raw materials, distributors and customers.
Chapter 13: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 14: The main points and conclusions of the report.

FAQ for this report

How fast is Chemotherapy Induced Peripheral Neuropathy Treatment Market growing?

Ans: The Chemotherapy Induced Peripheral Neuropathy Treatment Market witnessing a CAGR of 6.4 during the forecast period 2024-2030.

What is the Chemotherapy Induced Peripheral Neuropathy Treatment Market size in 2030?

Ans: The Chemotherapy Induced Peripheral Neuropathy Treatment Market size in 2030 will be US$ 2599.2 million.

What is the Chemotherapy Induced Peripheral Neuropathy Treatment Market share by region?

Ans: Americas is the largest market with about 47% market share. Europe is follower, accounting for about 27% market share.

Who are the main players in the Chemotherapy Induced Peripheral Neuropathy Treatment Market report?

Ans: The main players in the Chemotherapy Induced Peripheral Neuropathy Treatment Market are Regenacy Pharmaceuticals, MAKScientific LLC, Metys Pharmaceuticals AG, Nemus Bioscience Inc, PledPharma, Sova Pharmaceuticals Inc, DermaXon LLC, Kineta Inc, Krenitsky Pharmaceuticals Inc, PeriphaGen, Apexian Pharma, WinSanTor

What are the Application segmentation covered in the Chemotherapy Induced Peripheral Neuropathy Treatment Market report?

Ans: The Applications covered in the Chemotherapy Induced Peripheral Neuropathy Treatment Market report are Platinum Agents, Taxanes, Vinca Alkaloids, Others

What are the Type segmentation covered in the Chemotherapy Induced Peripheral Neuropathy Treatment Market report?

Ans: The Types covered in the Chemotherapy Induced Peripheral Neuropathy Treatment Market report are Calcium Channel α2-delta Ligands, Antidepressants, Opioids, Others

1 Study Coverage

1.1 Chemotherapy Induced Peripheral Neuropathy Treatment Product Introduction

1.2 Market by Type

1.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030

1.2.2 Calcium Channel α2-delta Ligands

1.2.3 Antidepressants

1.2.4 Opioids

1.2.5 Others

1.3 Market by Application

1.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030

1.3.2 Platinum Agents

1.3.3 Taxanes

1.3.4 Vinca Alkaloids

1.3.5 Others

1.4 Assumptions and Limitations

1.5 Study Objectives

1.6 Years Considered

2 Executive Summary

2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts 2019-2030

2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region

2.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region: 2019 VS 2023 VS 2030

2.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2019-2024)

2.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2025-2030)

2.2.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2019-2030)

2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Estimates and Forecasts 2019-2030

2.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region

2.4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region: 2019 VS 2023 VS 2030

2.4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2019-2024)

2.4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2025-2030)

2.4.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2019-2030)

2.5 US & Canada

2.6 Europe

2.7 China

2.8 Asia (excluding China)

2.9 Middle East, Africa and Latin America

3 Competition by Manufactures

3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers

3.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (2019-2024)

3.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Manufacturers (2019-2024)

3.1.3 Global Top 10 and Top 5 Largest Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment in 2023

3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers

3.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers (2019-2024)

3.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Manufacturers (2019-2024)

3.2.3 Global Top 10 and Top 5 Companies by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2023

3.3 Global Key Players of Chemotherapy Induced Peripheral Neuropathy Treatment, Industry Ranking, 2022 VS 2023 VS 2024

3.4 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Price by Manufacturers

3.5 Analysis of Competitive Landscape

3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)

3.5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

3.6 Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Manufacturing Base Distribution and Headquarters

3.7 Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Product Offered and Application

3.8 Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Date of Enter into This Industry

3.9 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type

4.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type

4.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historical Sales by Type (2019-2024)

4.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Sales by Type (2025-2030)

4.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2019-2030)

4.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type

4.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historical Revenue by Type (2019-2024)

4.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Revenue by Type (2025-2030)

4.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2019-2030)

4.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type

4.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2019-2024)

4.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Type (2025-2030)

5 Market Size by Application

5.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application

5.1.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historical Sales by Application (2019-2024)

5.1.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Sales by Application (2025-2030)

5.1.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2019-2030)

5.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application

5.2.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Historical Revenue by Application (2019-2024)

5.2.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Forecasted Revenue by Application (2025-2030)

5.2.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2019-2030)

5.3 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application

5.3.1 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2019-2024)

5.3.2 Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Application (2025-2030)

6 US & Canada

6.1 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type

6.1.1 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2030)

6.1.2 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2030)

6.2 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application

6.2.1 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2030)

6.2.2 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2030)

6.3 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country

6.3.1 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country: 2019 VS 2023 VS 2030

6.3.2 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2019-2030)

6.3.3 US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2019-2030)

6.3.4 US

6.3.5 Canada

7 Europe

7.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type

7.1.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2030)

7.1.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2030)

7.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application

7.2.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2030)

7.2.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2030)

7.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Country

7.3.1 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country: 2019 VS 2023 VS 2030

7.3.2 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2019-2030)

7.3.3 Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2019-2030)

7.3.4 Germany

7.3.5 France

7.3.6 U.K.

7.3.7 Italy

7.3.8 Russia

8 China

8.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Size

8.1.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales (2019-2030)

8.1.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030)

8.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application

8.2.1 China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2030)

8.2.2 China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2030)

9 Asia (excluding China)

9.1 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type

9.1.1 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2030)

9.1.2 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2030)

9.2 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application

9.2.1 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2030)

9.2.2 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2030)

9.3 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region

9.3.1 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region: 2019 VS 2023 VS 2030

9.3.2 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2019-2030)

9.3.3 Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2019-2030)

9.3.4 Japan

9.3.5 South Korea

9.3.6 China Taiwan

9.3.7 Southeast Asia

9.3.8 India

10 Middle East, Africa and Latin America

10.1 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Type

10.1.1 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2030)

10.1.2 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2030)

10.2 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Market Size by Application

10.2.1 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2030)

10.2.2 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2030)

10.3 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country

10.3.1 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country: 2019 VS 2023 VS 2030

10.3.2 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2019-2030)

10.3.3 Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2019-2030)

10.3.4 Brazil

10.3.5 Mexico

10.3.6 Turkey

10.3.7 Israel

10.3.8 GCC Countries

11 Company Profiles

11.1 Aptinyx Inc

11.1.1 Aptinyx Inc Company Information

11.1.2 Aptinyx Inc Overview

11.1.3 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.1.4 Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.1.5 Aptinyx Inc Recent Developments

11.2 Asahi Kasei Pharma Corp

11.2.1 Asahi Kasei Pharma Corp Company Information

11.2.2 Asahi Kasei Pharma Corp Overview

11.2.3 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.2.4 Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.2.5 Asahi Kasei Pharma Corp Recent Developments

11.3 Regenacy Pharmaceuticals

11.3.1 Regenacy Pharmaceuticals Company Information

11.3.2 Regenacy Pharmaceuticals Overview

11.3.3 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.3.4 Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.3.5 Regenacy Pharmaceuticals Recent Developments

11.4 MAKScientific LLC

11.4.1 MAKScientific LLC Company Information

11.4.2 MAKScientific LLC Overview

11.4.3 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.4.4 MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.4.5 MAKScientific LLC Recent Developments

11.5 Metys Pharmaceuticals AG

11.5.1 Metys Pharmaceuticals AG Company Information

11.5.2 Metys Pharmaceuticals AG Overview

11.5.3 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.5.4 Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.5.5 Metys Pharmaceuticals AG Recent Developments

11.6 Nemus Bioscience Inc

11.6.1 Nemus Bioscience Inc Company Information

11.6.2 Nemus Bioscience Inc Overview

11.6.3 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.6.4 Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.6.5 Nemus Bioscience Inc Recent Developments

11.7 PledPharma

11.7.1 PledPharma Company Information

11.7.2 PledPharma Overview

11.7.3 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.7.4 PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.7.5 PledPharma Recent Developments

11.8 Sova Pharmaceuticals Inc

11.8.1 Sova Pharmaceuticals Inc Company Information

11.8.2 Sova Pharmaceuticals Inc Overview

11.8.3 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.8.4 Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.8.5 Sova Pharmaceuticals Inc Recent Developments

11.9 DermaXon LLC

11.9.1 DermaXon LLC Company Information

11.9.2 DermaXon LLC Overview

11.9.3 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.9.4 DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.9.5 DermaXon LLC Recent Developments

11.10 Kineta Inc

11.10.1 Kineta Inc Company Information

11.10.2 Kineta Inc Overview

11.10.3 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.10.4 Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.10.5 Kineta Inc Recent Developments

11.11 Krenitsky Pharmaceuticals Inc

11.11.1 Krenitsky Pharmaceuticals Inc Company Information

11.11.2 Krenitsky Pharmaceuticals Inc Overview

11.11.3 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.11.4 Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.11.5 Krenitsky Pharmaceuticals Inc Recent Developments

11.12 PeriphaGen

11.12.1 PeriphaGen Company Information

11.12.2 PeriphaGen Overview

11.12.3 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.12.4 PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.12.5 PeriphaGen Recent Developments

11.13 Apexian Pharma

11.13.1 Apexian Pharma Company Information

11.13.2 Apexian Pharma Overview

11.13.3 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.13.4 Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.13.5 Apexian Pharma Recent Developments

11.14 WinSanTor

11.14.1 WinSanTor Company Information

11.14.2 WinSanTor Overview

11.14.3 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales, Price, Revenue and Gross Margin (2019-2024)

11.14.4 WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

11.14.5 WinSanTor Recent Developments

12 Industry Chain and Sales Channels Analysis

12.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Chain Analysis

12.2 Chemotherapy Induced Peripheral Neuropathy Treatment Key Raw Materials

12.2.1 Key Raw Materials

12.2.2 Raw Materials Key Suppliers

12.3 Chemotherapy Induced Peripheral Neuropathy Treatment Production Mode & Process

12.4 Chemotherapy Induced Peripheral Neuropathy Treatment Sales and Marketing

12.4.1 Chemotherapy Induced Peripheral Neuropathy Treatment Sales Channels

12.4.2 Chemotherapy Induced Peripheral Neuropathy Treatment Distributors

12.5 Chemotherapy Induced Peripheral Neuropathy Treatment Customers

13 Market Dynamics

13.1 Chemotherapy Induced Peripheral Neuropathy Treatment Industry Trends

13.2 Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers

13.3 Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges

13.4 Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints

14 Key Findings in The Global Chemotherapy Induced Peripheral Neuropathy Treatment Study

15 Appendix

15.1 Research Methodology

15.1.1 Methodology/Research Approach

15.1.2 Data Source

15.2 Author Details

15.3 Disclaimer

FEATURED COMPANIES

Aptinyx Inc

Asahi Kasei Pharma Corp

Regenacy Pharmaceuticals

MAKScientific

Metys Pharmaceuticals AG

Nemus Bioscience Inc

PledPharma

Sova Pharmaceuticals Inc

DermaXon LLC

Kineta

Krenitsky Pharmaceuticals Inc

PeriphaGen Inc

Apexian Pharma

WinSanTor

List of Tables

Table 1. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Table 2. Major Manufacturers of Calcium Channel α2-delta Ligands

Table 3. Major Manufacturers of Antidepressants

Table 4. Major Manufacturers of Opioids

Table 5. Major Manufacturers of Others

Table 6. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Table 7. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2019-2024) & (US$ Million)

Table 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2025-2030) & (US$ Million)

Table 10. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2019-2024)

Table 11. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2025-2030)

Table 12. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Grow Rate (CAGR) by Region: 2019 VS 2023 VS 2030 (US$ Million)

Table 13. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2019-2024) & (K Units)

Table 14. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2025-2030) & (K Units)

Table 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2019-2024)

Table 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2025-2030)

Table 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Manufacturers (2019-2024) & (K Units)

Table 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Manufacturers (2019-2024)

Table 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Manufacturers (2019-2024) & (US$ Million)

Table 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Manufacturers (2019-2024)

Table 21. Global Key Players of Chemotherapy Induced Peripheral Neuropathy Treatment, Industry Ranking, 2022 VS 2023 VS 2024

Table 22. Chemotherapy Induced Peripheral Neuropathy Treatment Price by Manufacturers 2019-2024 (US$/Unit)

Table 23. Global Chemotherapy Induced Peripheral Neuropathy Treatment Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 24. Global Chemotherapy Induced Peripheral Neuropathy Treatment by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Chemotherapy Induced Peripheral Neuropathy Treatment as of 2023)

Table 25. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Manufacturing Base Distribution and Headquarters

Table 26. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Product Offered and Application

Table 27. Global Key Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment, Date of Enter into This Industry

Table 28. Mergers & Acquisitions, Expansion Plans

Table 29. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2024) & (K Units)

Table 30. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2025-2030) & (K Units)

Table 31. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2019-2024)

Table 32. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Type (2025-2030)

Table 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2024) & (US$ Million)

Table 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2025-2030) & (US$ Million)

Table 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2019-2024)

Table 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Type (2025-2030)

Table 37. Chemotherapy Induced Peripheral Neuropathy Treatment Price by Type (2019-2024) & (US$/Unit)

Table 38. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Type (2025-2030) & (US$/Unit)

Table 39. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2024) & (K Units)

Table 40. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2025-2030) & (K Units)

Table 41. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2019-2024)

Table 42. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Application (2025-2030)

Table 43. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2024) & (US$ Million)

Table 44. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2025-2030) & (US$ Million)

Table 45. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2019-2024)

Table 46. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Application (2025-2030)

Table 47. Chemotherapy Induced Peripheral Neuropathy Treatment Price by Application (2019-2024) & (US$/Unit)

Table 48. Global Chemotherapy Induced Peripheral Neuropathy Treatment Price Forecast by Application (2025-2030) & (US$/Unit)

Table 49. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2024) & (K Units)

Table 50. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2025-2030) & (K Units)

Table 51. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2024) & (US$ Million)

Table 52. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2025-2030) & (US$ Million)

Table 53. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2024) & (K Units)

Table 54. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2025-2030) & (K Units)

Table 55. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2024) & (US$ Million)

Table 56. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2025-2030) & (US$ Million)

Table 57. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 58. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 59. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 60. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2019-2024) & (K Units)

Table 61. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2025-2030) & (K Units)

Table 62. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2024) & (K Units)

Table 63. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2025-2030) & (K Units)

Table 64. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2024) & (US$ Million)

Table 65. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2025-2030) & (US$ Million)

Table 66. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2024) & (K Units)

Table 67. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2025-2030) & (K Units)

Table 68. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2024) & (US$ Million)

Table 69. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2025-2030) & (US$ Million)

Table 70. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 71. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 72. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 73. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2019-2024) & (K Units)

Table 74. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2025-2030) & (K Units)

Table 75. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2024) & (K Units)

Table 76. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2025-2030) & (K Units)

Table 77. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2024) & (US$ Million)

Table 78. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2025-2030) & (US$ Million)

Table 79. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2024) & (K Units)

Table 80. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2025-2030) & (K Units)

Table 81. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2024) & (US$ Million)

Table 82. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2025-2030) & (US$ Million)

Table 83. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2024) & (K Units)

Table 84. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2025-2030) & (K Units)

Table 85. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2024) & (US$ Million)

Table 86. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2025-2030) & (US$ Million)

Table 87. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2024) & (K Units)

Table 88. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2025-2030) & (K Units)

Table 89. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2024) & (US$ Million)

Table 90. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2025-2030) & (US$ Million)

Table 91. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 92. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2019-2024) & (US$ Million)

Table 93. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Region (2025-2030) & (US$ Million)

Table 94. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2019-2024) & (K Units)

Table 95. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Region (2025-2030) & (K Units)

Table 96. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2019-2024) & (K Units)

Table 97. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Type (2025-2030) & (K Units)

Table 98. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2019-2024) & (US$ Million)

Table 99. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Type (2025-2030) & (US$ Million)

Table 100. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2019-2024) & (K Units)

Table 101. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Application (2025-2030) & (K Units)

Table 102. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2019-2024) & (US$ Million)

Table 103. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Application (2025-2030) & (US$ Million)

Table 104. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Grow Rate (CAGR) by Country: 2019 VS 2023 VS 2030 (US$ Million)

Table 105. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2019-2024) & (US$ Million)

Table 106. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue by Country (2025-2030) & (US$ Million)

Table 107. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2019-2024) & (K Units)

Table 108. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales by Country (2025-2030) & (K Units)

Table 109. Aptinyx Inc Company Information

Table 110. Aptinyx Inc Description and Major Businesses

Table 111. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 112. Aptinyx Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 113. Aptinyx Inc Recent Developments

Table 114. Asahi Kasei Pharma Corp Company Information

Table 115. Asahi Kasei Pharma Corp Description and Major Businesses

Table 116. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 117. Asahi Kasei Pharma Corp Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 118. Asahi Kasei Pharma Corp Recent Developments

Table 119. Regenacy Pharmaceuticals Company Information

Table 120. Regenacy Pharmaceuticals Description and Major Businesses

Table 121. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 122. Regenacy Pharmaceuticals Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 123. Regenacy Pharmaceuticals Recent Developments

Table 124. MAKScientific LLC Company Information

Table 125. MAKScientific LLC Description and Major Businesses

Table 126. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 127. MAKScientific LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 128. MAKScientific LLC Recent Developments

Table 129. Metys Pharmaceuticals AG Company Information

Table 130. Metys Pharmaceuticals AG Description and Major Businesses

Table 131. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 132. Metys Pharmaceuticals AG Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 133. Metys Pharmaceuticals AG Recent Developments

Table 134. Nemus Bioscience Inc Company Information

Table 135. Nemus Bioscience Inc Description and Major Businesses

Table 136. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 137. Nemus Bioscience Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 138. Nemus Bioscience Inc Recent Developments

Table 139. PledPharma Company Information

Table 140. PledPharma Description and Major Businesses

Table 141. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 142. PledPharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 143. PledPharma Recent Developments

Table 144. Sova Pharmaceuticals Inc Company Information

Table 145. Sova Pharmaceuticals Inc Description and Major Businesses

Table 146. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 147. Sova Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 148. Sova Pharmaceuticals Inc Recent Developments

Table 149. DermaXon LLC Company Information

Table 150. DermaXon LLC Description and Major Businesses

Table 151. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 152. DermaXon LLC Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 153. DermaXon LLC Recent Developments

Table 154. Kineta Inc Company Information

Table 155. Kineta Inc Description and Major Businesses

Table 156. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 157. Kineta Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 158. Kineta Inc Recent Developments

Table 159. Krenitsky Pharmaceuticals Inc Company Information

Table 160. Krenitsky Pharmaceuticals Inc Description and Major Businesses

Table 161. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 162. Krenitsky Pharmaceuticals Inc Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 163. Krenitsky Pharmaceuticals Inc Recent Developments

Table 164. PeriphaGen Company Information

Table 165. PeriphaGen Description and Major Businesses

Table 166. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 167. PeriphaGen Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 168. PeriphaGen Recent Developments

Table 169. Apexian Pharma Company Information

Table 170. Apexian Pharma Description and Major Businesses

Table 171. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 172. Apexian Pharma Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 173. Apexian Pharma Recent Developments

Table 174. WinSanTor Company Information

Table 175. WinSanTor Description and Major Businesses

Table 176. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2019-2024)

Table 177. WinSanTor Chemotherapy Induced Peripheral Neuropathy Treatment Product Model Numbers, Pictures, Descriptions and Specifications

Table 178. WinSanTor Recent Developments

Table 179. Key Raw Materials Lists

Table 180. Raw Materials Key Suppliers Lists

Table 181. Chemotherapy Induced Peripheral Neuropathy Treatment Distributors List

Table 182. Chemotherapy Induced Peripheral Neuropathy Treatment Customers List

Table 183. Chemotherapy Induced Peripheral Neuropathy Treatment Market Trends

Table 184. Chemotherapy Induced Peripheral Neuropathy Treatment Market Drivers

Table 185. Chemotherapy Induced Peripheral Neuropathy Treatment Market Challenges

Table 186. Chemotherapy Induced Peripheral Neuropathy Treatment Market Restraints

Table 187. Research Programs/Design for This Report

Table 188. Key Data Information from Secondary Sources

Table 189. Key Data Information from Primary Sources

List of Figures

Figure 1. Chemotherapy Induced Peripheral Neuropathy Treatment Product Picture

Figure 2. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Type, 2019 VS 2023 VS 2030 (US$ Million)

Figure 3. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Type in 2023 & 2030

Figure 4. Calcium Channel α2-delta Ligands Product Picture

Figure 5. Antidepressants Product Picture

Figure 6. Opioids Product Picture

Figure 7. Others Product Picture

Figure 8. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Growth Rate by Application, 2019 VS 2023 VS 2030 (US$ Million)

Figure 9. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Application in 2023 & 2030

Figure 10. Platinum Agents

Figure 11. Taxanes

Figure 12. Vinca Alkaloids

Figure 13. Others

Figure 14. Chemotherapy Induced Peripheral Neuropathy Treatment Report Years Considered

Figure 15. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue, (US$ Million), 2019 VS 2023 VS 2030

Figure 16. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue 2019-2030 (US$ Million)

Figure 17. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region in Percentage: 2023 Versus 2030

Figure 18. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Region (2019-2030)

Figure 19. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales 2019-2030 ((K Units)

Figure 20. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Region (2019-2030)

Figure 21. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2019-2030) & (K Units)

Figure 22. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue YoY (2019-2030) & (US$ Million)

Figure 23. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2019-2030) & (K Units)

Figure 24. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue YoY (2019-2030) & (US$ Million)

Figure 25. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2019-2030) & (K Units)

Figure 26. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue YoY (2019-2030) & (US$ Million)

Figure 27. Asia (excluding China) Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2019-2030) & (K Units)

Figure 28. Asia (excluding China) Chemotherapy Induced Peripheral Neuropathy Treatment Revenue YoY (2019-2030) & (US$ Million)

Figure 29. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales YoY (2019-2030) & (K Units)

Figure 30. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue YoY (2019-2030) & (US$ Million)

Figure 31. The Chemotherapy Induced Peripheral Neuropathy Treatment Market Share of Top 10 and Top 5 Largest Manufacturers Around the World in 2023

Figure 32. The Top 5 and 10 Largest Manufacturers of Chemotherapy Induced Peripheral Neuropathy Treatment in the World: Market Share by Chemotherapy Induced Peripheral Neuropathy Treatment Revenue in 2023

Figure 33. Global Chemotherapy Induced Peripheral Neuropathy Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023

Figure 34. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2019-2030)

Figure 35. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2019-2030)

Figure 36. Global Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2019-2030)

Figure 37. Global Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2019-2030)

Figure 38. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2019-2030)

Figure 39. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2019-2030)

Figure 40. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2019-2030)

Figure 41. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2019-2030)

Figure 42. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country (2019-2030)

Figure 43. US & Canada Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Country (2019-2030)

Figure 44. U.S. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 45. Canada Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 46. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2019-2030)

Figure 47. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2019-2030)

Figure 48. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2019-2030)

Figure 49. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2019-2030)

Figure 50. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country (2019-2030)

Figure 51. Europe Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Country (2019-2030)

Figure 52. Germany Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 53. France Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 54. U.K. Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 55. Italy Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 56. Russia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 57. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2019-2030)

Figure 58. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2019-2030)

Figure 59. China Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2019-2030)

Figure 60. China Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2019-2030)

Figure 61. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2019-2030)

Figure 62. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2019-2030)

Figure 63. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2019-2030)

Figure 64. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2019-2030)

Figure 65. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Region (2019-2030)

Figure 66. Asia Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Region (2019-2030)

Figure 67. Japan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 68. South Korea Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 69. China Taiwan Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 70. Southeast Asia Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 71. India Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 72. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Type (2019-2030)

Figure 73. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Type (2019-2030)

Figure 74. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Market Share by Application (2019-2030)

Figure 75. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Market Share by Application (2019-2030)

Figure 76. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Revenue Share by Country (2019-2030)

Figure 77. Middle East, Africa and Latin America Chemotherapy Induced Peripheral Neuropathy Treatment Sales Share by Country (2019-2030)

Figure 78. Brazil Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 79. Mexico Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 80. Turkey Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 81. Israel Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 82. GCC Countries Chemotherapy Induced Peripheral Neuropathy Treatment Revenue (2019-2030) & (US$ Million)

Figure 83. Chemotherapy Induced Peripheral Neuropathy Treatment Value Chain

Figure 84. Chemotherapy Induced Peripheral Neuropathy Treatment Production Process

Figure 85. Channels of Distribution

Figure 86. Distributors Profiles

Figure 87. Bottom-up and Top-down Approaches for This Report

Figure 88. Data Triangulation

Figure 89. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$4900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$7350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$9800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions